Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 General characteristics and laboratory markers of assessed patients with rheumatoid arthritis and control subjects

From: Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis

  RA total RA MTX RA biologic Control subjects
No. of subjects 41 12 29 60
Age, years 58.24 ± 9.72 58.67 ± 9.88 58.07 ± 9.88 58.42 ± 4.41
Disease duration. years 12.15 ± 8.03 11.00 ± 8.63 12.62 ± 7.87
RF positivity, % 70% 82% 66%
Anti-CCP positivity, % 65% 75% 64%
MTX duration, years 6.15 ± 5.82 5.83 ± 4.57 6.28 ± 3.54
MTX dose, mg/week 14.63 ± 6.11 14.17 ± 5.15 14.83 ± 6.54
Biologic duration, years 5.31 ± 2.04 5.31 ± 2.04
DAS28 2.44 ± 0.87 2.88 ± 0.75 2.26 ± 0.86
ESR, mm/h 17.07 ± 15.09 17.00 ± 9.16 17.10 ± 17.10 5.30 ± 2.40
hsCRP, mg/L 3.93 ± 4.53 5.31 ± 3.90 3.36 ± 4.70 0.30 ± 0.30
BMI, kg/m2 28.38 ± 5.51 28.08 ± 6.77 28.51 ± 5.02 30.20 ± 8.70
TC, mmol/L 5.34 ± 1.08 5.63 ± 1.00 5.23 ± 1.10 5.27 ± 1.15
HDL-C, mmol/L 1.47 ± 0.43 1.38 ± 0.53 1.49 ± 0.40 1.70 ± 0.42
TC/HDL-C ratio 3.94 ± 1.36 4.70 ± 3.73 3.73 ± 1.20 3.62 ± 0.95
LDL-C, mmol/L 3.17 ± 0.82 3.36 ± 0.90 3.12 ± 0.81 3.40 ± 0.94
TG, mmol/L 1.46 ± 0.68 1.53 ± 0.76 1.43 ± 0.66 1.49 ± 0.61
Lp(a), ng/L 260.14 ± 317.20 345.29 ± 426.55 239.59 ± 290.74
ApoA/ApoB ratio 1.81 ± 0.51 1.71 ± 0.49 1.83 ± 0.53
  1. Abbreviations: Apo Apolipoprotein, BMI Body mass index, CCP Cyclic citrullinated peptide, CRC Cerebrovascular reserve capacity, DAS28 28-joint Disease Activity Score, ESR Erythrocyte sedimentation rate, HDL-C High-density lipoprotein cholesterol, hsCRP High-sensitivity C-reactive protein, LDL-C Low-density lipoprotein cholesterol, Lp(a) Serum lipoprotein A, MTX Methotrexate, RA Rheumatoid arthritis, RF Rheumatoid factor, TC Total cholesterol, TG Triglyceride